PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline Analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Hepatic encephalopathy – Market size and forecast 2018-2023
• Diabetic encephalopathy – Market size and forecast 2018-2023
• Infectious encephalopathy – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Emergence of novel treatment targets for encephalopathy
• Increase in FDA drug approval for diseases associated with encephalopathy
• Increase in adoption of technological advances for treating encephalopathy
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Market positioning of vendors
• Bausch Health
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global CNS disorder drugs market
Exhibit 02: Segments of global cns disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under phase I/II development
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Hepatic encephalopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Hepatic encephalopathy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Diabetic encephalopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Diabetic encephalopathy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Infectious encephalopathy – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Infectious encephalopathy – Year-over-year growth 2019-2023 (%)
Exhibit 26: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Others – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in APAC
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Bausch Health – Vendor overview
Exhibit 50: Bausch Health – Business segments
Exhibit 51: Bausch Health – Organizational developments
Exhibit 52: Bausch Health – Geographic focus
Exhibit 53: Bausch Health – Segment focus
Exhibit 54: Bausch Health – Key offerings
【掲載企業】
Bausch Health